// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Clinical Outcomes for Patients of High Body Weight on Apixaban or Rivaroxaban

G. Bahra - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Ischemic stroke

rivaroxaban

Clinical Performance of the Tina-Quant D-Dimer Gen 2 Assay on the Cobas t 711 Analyser for Evaluation of Patients with Suspected Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE)

T. Bertsch - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Deep vein thrombosis

N/A

Clinically Relevant Differences between Two New Generation VWF: GPIbR Assays in a Patient with Acquired von Willebrand Syndrome – Case Report

K. Mayger - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Clot Formation, Ultrastructure and Lysis in Patients with Acute Phase Myocardial Infarction

S.R. Baker - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

N/A

Coagulation Factor XII Binds to the Opportunistic Pathogen, Candida albicans and Promotes Biofilm Formation

M.L. Williams - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

ALS-3

Combined Gene and Cell Therapy for the Treatment of Hemophilia A within an Implantable Therapeutic Device

C. Olgasi - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

Comparison of a Novel Viscoelastic Device with Standard Laboratory Tests for its Clinical Validation in Peri-Operative Cardiac Patients

B. Brannan - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Comparison of Coagulation Parameters Associated with Fibrinogen Concentrate and Cryoprecipitate for Treatment of Bleeding in Patients Undergoing Cytoreductive Surgery for Pseudomyxoma Peritonei: Results from the FORMA-05 Study

A. Roy - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gelatinous peritoneal

FVIII

Comparison of Visual versus Reader Results of the Point of Care Test of Direct Oral Anticoagulants from Urine Samples

J. Harenberg - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

rivaroxaban

Complement Regulator Factor H is a Cofactor for Thrombin in both Pro- and Anticoagulant Roles

G. McCluskey - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Thrombomodulin alfa

Critical Role for Platelet Ral GTPases in the Regulation of Venous Thrombosis

Y. Li - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Data Mining: An Innovative Approach to Optimise Post-Hoc Analyses of Large Trial Data Sets into Clinically Relevant Results

P. Chowdary - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Desmopressin for Procedures or Radiological Interventions (DRIVE): Participant Characteristics in a Placebo-Controlled Double-Blind, Randomised Feasibility Trial of Desmopressin in Thrombocytopenic Critically Ill Patients Prior to Procedures

M. Desborough - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Desmopressin

Desmopressin for Reversal of Antiplatelet Drugs in Stroke due to Haemorrhage (DASH): Interim Report on Recruitment from a Phase II Double Blind Randomised Controlled Trial

M. Desborough - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

Desmopressin

Desmopressin Response and Clinical Outcome in Bleeding Disorders: A 30 Year Retrospective Analysis

M.R. Peralta - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Desmopressin

Dietary Intake of Zinc Modulates Platelet Intracellular Levels and Haemostatic Parameters

U. Sumya - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Differences in Outcomes between Real-World vs Clinical Trial in Atrial Fibrillation and Chronic Kidney Disease

W.Y. Ding - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

N/A

Differences in the Prediction of the Time above Target in Hemophilia A Patients Using a Chromogenic Assay and a One-stage Assay in Model-informed Precision Dosing

D.W. Uster - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

Differences in Treatment and Outcomes in Recently Diagnosed Atrial Fibrillation between the Netherlands and Belgium: Results from the GARFIELD-AF Registry

J. Seelig - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Direct Temporal Labelling of Platelets in vivo Allows Monitoring and Examination of Newly Formed and Aged Platelets to Reveal Changes in Receptor Expression Levels and Loss of Functional Ability

P. Armstrong - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved